Actemra and Joint destruction - a phase IV clinical study of FDA data

Summary:

Joint destruction is reported as a side effect among people who take Actemra (tocilizumab), especially for people who are female, 50-59 old, have been taking the drug for 1 - 6 months also take Orencia, and have Juvenile rheumatoid arthritis.

The phase IV clinical study analyzes which people have Joint destruction when taking Actemra. It is created by eHealthMe based on reports of 102,551 people who have side effects when taking Actemra from the FDA, and is updated regularly.

What is Actemra?

Actemra has active ingredients of tocilizumab. It is often used in rheumatoid arthritis. eHealthMe is studying from 102,759 Actemra users. Check the latest studies of Actemra.

What is Joint destruction?

Joint destruction (joint damage) is found to be associated with 136 drugs and 419 conditions by eHealthMe. Check the latest studies of Joint destruction.

On Aug, 10, 2026

102,551 people reported to have side effects when taking Actemra.
Among them, 571 people (0.56%) have Joint destruction.

Among these 571 people:

* Approximation only. Some reports may have incomplete information.

Do you take Actemra and have Joint destruction?

- Check whether Joint destruction is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Actemra:

Actemra (102,759 reports)

Joint destruction treatments and more:

Joint destruction (2,041 reports)

How severe was Joint destruction and when was it recovered:

Joint destruction in Actemra

Expand to all the drugs that have ingredients of tocilizumab:

Joint destruction and drugs with ingredients of tocilizumab (635 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Actemra:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Joint destruction:

Joint destruction (136 drugs)

Browse all the conditions that are associated with Joint destruction:

Joint destruction (419 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on tocilizumab (the active ingredients of Actemra) and Actemra (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.